HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD. Hubei Biocause Pharmaceutical Co., Ltd. Share Price
Equities
000627
CNE000000F48
Life & Health Insurance
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.35 CNY | +4.91% |
|
+2.62% | -17.25% |
| 04-15 | Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01-15 | Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023 | MT |
| Sales 2021 | 48.7B 6.72B 538B | Sales 2022 | 49.31B 6.81B 545B | Capitalization | 15.61B 2.15B 173B |
|---|---|---|---|---|---|
| Net income 2021 | 471M 65M 5.21B | Net income 2022 | 274M 37.81M 3.03B | EV / Sales 2021 | 0.18 x |
| Net cash position 2021 | 7.58B 1.05B 83.79B | Net Debt 2022 | 1.76B 243M 19.46B | EV / Sales 2022 | 0.35 x |
| P/E ratio 2021 |
33.1
x | P/E ratio 2022 |
52.7
x | Employees | 2,098 |
| Yield 2021 |
0.15% | Yield 2022 |
3.48% | Free-Float | 31.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.91% | ||
| 1 week | +2.62% | ||
| Current month | -4.86% | ||
| 1 month | -5.24% | ||
| 3 months | -19.24% | ||
| 6 months | -24.19% | ||
| Current year | -17.25% |
1 week
2.19
2.37
1 month
2.192.59
Current year
2.113.08
1 year
2.113.91
3 years
2.114.08
5 years
2.117.95
10 years
2.1117.30
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Xia Zhou
CEO | Chief Executive Officer | 52 | 25/05/20 |
Jian Qiang Shen
CHM | Chairman | 52 | 31/05/96 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 25/05/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Qian Liu
CHM | Chairman | 61 | 10/03/15 |
Yunhua Xiao
BRD | Director/Board Member | 62 | 31/03/03 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 25/05/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.35 | +4.91% | 48,942,090 |
| 25/04/24 | 2.24 | +0.45% | 23,316,370 |
| 24/04/24 | 2.23 | +1.36% | 20,403,300 |
| 23/04/24 | 2.2 | -2.22% | 27,079,900 |
| 22/04/24 | 2.25 | -1.75% | 20,910,720 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Companyâs products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.
Sector
Life & Health Insurance
Calendar
29/04/2024
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.25% | 1.6B | |
| +14.78% | 79.51B | |
| +6.49% | 50.92B | |
| +1.35% | 48.11B | |
| +6.55% | 39.71B | |
| +19.34% | 37.78B | |
| +2.84% | 30.07B | |
| -7.77% | 27.56B | |
| -18.42% | 24.71B | |
| +6.89% | 21.99B |
- Stock Market
- Equities
- 000627 Stock
